Beta RBD boost broadens antibody-mediated protection against SARS-CoV-2 variants in animal models.

Autor:	Sheward DJ; Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.; Division of Medical Virology, Institute of Infectious Diseases and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa., Mandolesi M; Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden., Urgard E; Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden., Kim C; Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden., Hanke L; Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden., Perez Vidakovics L; Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden., Pankow A; Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden., Smith NL; Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden., Castro Dopico X; Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden., McInerney GM; Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden., Coquet JM; Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden., Karlsson Hedestam GB; Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden., Murrell B; Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Jazyk:	angličtina
Zdroj:	Cell reports. Medicine [Cell Rep Med] 2021 Nov 16; Vol. 2 (11), pp. 100450. Date of Electronic Publication: 2021 Oct 23.
DOI:	10.1016/j.xcrm.2021.100450
Abstrakt:	Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) with resistance to neutralizing antibodies are threatening to undermine vaccine efficacy. Vaccination and infection have led to widespread humoral immunity against the pandemic founder (Wu-Hu-1). Against this background, it is critical to assess the outcomes of subsequent immunization with variant antigens. It is not yet clear whether heterotypic boosts would be compromised by original antigenic sin, where pre-existing responses to a prior variant dampen responses to a new one, or whether the memory B cell repertoire would bridge the gap between Wu-Hu-1 and VOCs. We show, in macaques immunized with Wu-Hu-1 spike, that a single dose of adjuvanted beta variant receptor binding domain (RBD) protein broadens neutralizing antibody responses to heterologous VOCs. Passive transfer of plasma sampled after Wu-Hu-1 spike immunization only partially protects K18-hACE2 mice from lethal challenge with a beta variant isolate, whereas plasma sampled following heterotypic RBD boost protects completely against disease. Competing Interests: The authors declare no competing interests. (© 2021 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu